Mymd Pharmaceuticals Inc. (MYMD) stock fell during pre-market, despite any current update

Mymd Pharmaceuticals Inc. (NASDAQ: MYMD) stock plunged by 1.34% at last close while the MYMD stock price declines by 5.28% in the pre-market trading session. MyMD Pharmaceuticals is a medical pharmaceutical start-up intended to build two unique therapeutic platforms that tackle the causes of disease and decline rather than just treating the symptoms.

>> 7 Top Picks for the Post-Pandemic Economy << 

MYMD stock’ Recent Development

MyMD Pharmaceuticals has stated that dosing for a Phase 2 trial of MYMD-1’s role in anti-aging will begin in the fourth quarter of 2021. This study’s interim effectiveness analysis is anticipated in the first quarter of 2022. The major purpose of this Phase 2 double-blind, placebo-controlled clinical research is to lower tumour necrosis factor-alpha (TNF-) levels in the blood. TNF- is a protein that produces inflammation in the body and aids in the ageing process.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Read More

MYMD-1’s oral dosing ease is a game-changer compared to currently available TNF-blockers, which must be administered by injection or infusion. There has never been an oral dose of a TNF inhibitor that has been authorized. Specificity and low toxicity are the second and third significant differentiators. Unlike previous medications, MYMD-1 is developed to selectively inhibit TNF- when it becomes overactive in autoimmune illnesses and cytokine storms, but not when it is acting as a first responder to any form of moderate infection. Furthermore, the medicine is not immunosuppressive and has not been demonstrated to induce major side effects like those seen with standard antibiotics.

Dr. Chapman commented,

According to a prominent investment bank, there are no FDA-approved medications for treating ageing problems and increasing healthy lifetime in humans, a market that is estimated to be worth at least $600 billion by 2025. TNF-blockers are the most profitable medications, with a global market worth roughly $40 billion each year, however according to the Nature Aging journal, a one-year gain in life expectancy is worth $38 trillion, and a ten-year increase is worth $367 trillion.

Most Popular

Related posts